The drug ‘aducanumab’ showed great promise in removing amyloid from the brains of people with Alzheimer’s disease. Amyloid deposits (‘plaques’) have been thought, perhaps incorrectly, to be the cause of brain deterioration in Alzheimer’s disease. But preliminary analysis of results from an incomplete very large trial did not show enough improvement to justify continuing the trial. Read more in the Time article: http://time.com/5557060/alzheimers-drug-aducanumab-trial-patient/